FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-028									
Fatimated average b	uurdon									

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

	=(5).				1 1100		tion 30(h) of the Ir						<u>-</u>			
1. Name and Address of Reporting Person*				2. Issuer Name <b>and</b> Ticker or Trading Symbol Sucampo Pharmaceuticals, Inc. [SCMP]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Edick Paul R											X	Director	10% (	Owner		
(Last) (First) (Middle) 805 KING FARM BLVD, SUITE 550					3. Date 08/01/	of Earliest Transa 2016	action (M	onth/E	Day/Year)		Officer (give title below)	Other below	(specify )			
					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) ROCKVI	LLE N	MD .	2	20850								X	Form filed by One Form filed by Mo Person			
(City)	(5	State)	(	Zip)									reisuli			
			Tabl	le I - Noi	n-Deriva	ative S	ecurities Acq	uired,	Disp	osed of, o	or Ben	eficially	Owned			
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(111341. 4)	
Common Stock <sup>(1)</sup> 08/01						2016		A		14,700	A	\$0	14,700	D		
			Та				urities Acqui s, warrants,		•	•		-	wned			
1 Title of	2	3 Trans	eaction	3A Deem	od /	ı	5 Number	6 Date E	varcie:	able and 7	Title and	8 P	rice of 9 Number of	of 10	11 Nature	

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

## Explanation of Responses:

 $1. \ Common \ stock \ granted \ consists \ of \ restricted \ stock \ units \ that \ vest \ in \ three \ equal \ annual \ installments \ beginning \ August \ 1, \ 2017.$ 

<u>/s/ Paul Edick</u> <u>08/03/2016</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.